Citadel Securities Starts Forest Laboratories (FRX) at Neutral; Forest Beginning to Clear
Tweet
Share
E-mailGet Alerts FRX Hot Sheet
Price: $12.00 --0%
Rating Summary:
10 Buy, 12 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 5 | Down: 5 | New: 5
Rating Summary:
10 Buy, 12 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 5 | Down: 5 | New: 5
Join SI Premium – FREE
Citadel Securities initiates coverage on Forest Laboratories (NYSE: FRX) with a Neutral. PT $36.00.
Citadel analyst says, "We believe Forest revenue growth from fiscal 2013 to fiscal 2016 will be dependent on successful launches of recently approved drugs Teflaro, Daliresp, and Viibryd. The success of these drugs, combined with modest gains in Savella and Bystolic sales, could potentially offset revenue declines of Lexapro and Namenda. Although good data and differentiated mechanisms of action support positive commercialization for Teflaro and Viibryd, a narrow indication and modest efficacy may hamper the sales potential and uptake of Daliresp. We estimate peak sales for Teflaro of $236.8MM in fiscal 2016, $514.5MM for Daliresp in fiscal 2016, and $661.9MM for Viibryd in fiscal 2016."
For more ratings news on Forest Laboratories click here and for the rating history of Forest Laboratories click here.
Shares of Forest Laboratories closed at $33.72 yesterday.
Citadel analyst says, "We believe Forest revenue growth from fiscal 2013 to fiscal 2016 will be dependent on successful launches of recently approved drugs Teflaro, Daliresp, and Viibryd. The success of these drugs, combined with modest gains in Savella and Bystolic sales, could potentially offset revenue declines of Lexapro and Namenda. Although good data and differentiated mechanisms of action support positive commercialization for Teflaro and Viibryd, a narrow indication and modest efficacy may hamper the sales potential and uptake of Daliresp. We estimate peak sales for Teflaro of $236.8MM in fiscal 2016, $514.5MM for Daliresp in fiscal 2016, and $661.9MM for Viibryd in fiscal 2016."
For more ratings news on Forest Laboratories click here and for the rating history of Forest Laboratories click here.
Shares of Forest Laboratories closed at $33.72 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- BMO Capital Starts Amapa Minerals Holdings (AMAP:CN) at Outperform
- BMO Capital Starts Alnylam Pharmaceuticals (ALNY) at Outperform
- CLSA Starts Beike (BEKE) at Outperform (2)
Create E-mail Alert Related Categories
New CoverageSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
